Seegene

Seegene EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Seegene (096530.KQ) as of Oct 28, 2026 is 7.06. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 12.35 — a change of -42.85% (lower).

EV/OCF

7.06

YoY

-42.85%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Seegene is 2025 7.06 . EV/OCF (Enterprise Value to Operating Cash Flow) of Seegene was 2024 12.35 . It decreases by -42.85% lower compared to the previous year.

The Seegene EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
72.79 KRW
Jan 1, 2019
36.94 KRW
Jan 1, 2020
2.18 KRW
Jan 1, 2021
2.21 KRW
Jan 1, 2022
1.91 KRW
Jan 1, 2023
11.11 KRW
Jan 1, 2024
12.35 KRW
Jan 1, 2025
7.06 KRW
The Seegene EV/OCF history
YEAREV/OCFYoY
7.06-42.85%
12.35+11.10%
11.11+482.11%
1.91-13.73%
2.21+1.51%
2.18-94.10%
36.94-49.25%
72.79-28.56%
101.90+65.45%
61.59-118.51%
-332.71-307.94%
160.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Seegene is 7.06 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Seegene changed from 12.35 to 7.06, representing a -42.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Seegene since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Seegene

All Key Metrics — Seegene